Endometrial carcinoma: The current role of adjuvant radiation

References

• Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics and Gynecology 1980; 56: 419–427
   PubMed Web of Science ®Google Scholar
• Alektiar K M, McKee A, Venkatraman E, McKee B, Zelefsky M J, Mychalczak B R, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 2002; 53: 707–713
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures. 2008
   Google Scholar
• Anderson J M, Stea B, Hallum A V, Rogoff E, Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 2000; 46: 417–425
   PubMed Web of Science ®Google Scholar
• Ashman J B, Connell P P, Yamada D, Rotmensch J, Waggoner S E, Mundt A J. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecologic Oncology 2001; 82: 338–343
   PubMedGoogle Scholar
• Carey M S, O'Connell G J, Johanson C R, Goodyear M D, Murphy K J, Daya D M, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecologic Oncology 1995; 57: 138–144
   PubMedGoogle Scholar
• Chadha M, Nanavati P J, Liu P, Fanning J, Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecologic Oncology 1999; 75: 103–107
   PubMed Web of Science ®Google Scholar
• Cohn D E, Horowitz N S, Mutch D G, Kim S M, Manolitsas T, Fowler J M. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer. Gynecologic Oncology 2002; 87: 243–246
   PubMed Web of Science ®Google Scholar
• Connell P P, Rotmensch J, Waggoner S, Mundt A J. The significance of adnexal involvement in endometrial carcinoma. Gynecologic Oncology 1999; 74: 74–79
   PubMedGoogle Scholar
• Creasman W T, Morrow C P, Bundy B N, Homesley H D, Graham J E, Heller P B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60: 2035–2041
   PubMed Web of Science ®Google Scholar
• Creutzberg C L, van Putten W L, Koper P C, Lybeert M L, Jobsen J J, Warlam-Rodenhuis C C, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics 2001; 51: 1246–1255
   PubMed Web of Science ®Google Scholar
• Creutzberg C L, van Putten W LJ, Koper P C, Lybeert M LM, Jobsen J J, Wárlám-Rodenhuis C C, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic Oncology 2003; 89: 201–209
   PubMed Web of Science ®Google Scholar
• Creutzberg C L, van Putten W L, Wárlám-Rodenhuis C C, van den Bergh A C, de Winter K A, Koper P C, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Journal of Clinical Oncology 2004; 22: 1234–1241
   PubMed Web of Science ®Google Scholar
• Eltabbakh G H, Piver M S, Hempling R E, Shin K H. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. International Journal of Radiation Oncology, Biology, Physics 1997; 38: 373–380
   PubMedGoogle Scholar
• Fakiris A J, Moore D H, Reddy S R, Look K Y, Yiannoutsos C T, Randall M E, et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97–01) study. Gynecologic Oncology 2005; 96: 818–823
   PubMed Web of Science ®Google Scholar
• Fanning J, Hoffman M L, Andrews S J, Harrah A W, Feldmeier J J. Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation. Gynecologic Oncology 2004; 93: 632–636
   PubMedGoogle Scholar
• Goff B A, Kato D, Schmidt R A, Ek M, Ferry J A, Muntz H G, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecologic Oncology 1994; 54: 264–268
   PubMed Web of Science ®Google Scholar
• Greven K M, Corn B, Lanciano R M, Case D, Randall M E. Pathologic stage III endometrial carcinoma: Significance of extrauterine sites. Radiation Oncology Investigations 1996; 4: 122–128
   Google Scholar
• Greven K M, Curran W J, Jr., Whittington R, Fanning J, Randall M E, Wilder J, et al. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. International Journal of Radiation Oncology, Biology, Physics 1989; 17: 35–39
   PubMed Web of Science ®Google Scholar
• Hogberg T, Rosenberg P, Kristensen G, de Oliveira C F, De Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). ASCO Meeting Abstracts 2007; 25: 5503
   Google Scholar
• Homesley H D, Filiaci V L, Gibbons S K, Long H J, Spirtos N M, Morris R T, et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108: S2
   Web of Science ®Google Scholar
• Huh W K, Powell M, Leath C A, 3rd, Straughn J M, Jr., Cohn D E, Gold M A, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecologic Oncology 2003; 91: 470–475
   PubMed Web of Science ®Google Scholar
• Inoue Y, Obata K, Abe K, Ohmura G, Doh K, Yoshioka T, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 1996; 78: 1447–1451
   PubMed Web of Science ®Google Scholar
• Jhingran A, Burke T W, Eifel P J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. International Journal of Radiation Oncology, Biology, Physics 2003; 56: 1366–1372
   PubMedGoogle Scholar
• Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. British Journal of Cancer 2003; 88: 245–250
   PubMedGoogle Scholar
• Keys H M, Roberts J A, Brunetto V L, Zaino R J, Spirtos N M, Bloss J D. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study [erratum appears in Gynecologic Oncology 94:241–242]. Gynecologic Oncology 2004; 92: 744–751
   PubMed Web of Science ®Google Scholar
• Kitchener H C, Redman C W. A study in the treatment of endometrial cancer: a randomised trial of lymphadenectomy in the treatment of endometrial cancer. International Journal of Gynaecological Cancer 2005; 15: 81–119
   PubMedGoogle Scholar
• Kong A, Simera I, Collingwood M, Williams C, Kitchener H, Cochrane Gynaecological Cancer G. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Annals of Oncology 2007; 18: 1595–1604
   PubMed Web of Science ®Google Scholar
• Lee C M, Szabo A, Shrieve D C, Macdonald O K, Gaffney D K. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma [erratum appears in JAMA 295:2482]. JAMA 2006; 295: 389–397
   PubMed Web of Science ®Google Scholar
• Macleod C, Fowler A, Duval P, D'costa I, Dalrymple C, Firth I, et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 1998; 42: 1033–1039
   PubMedGoogle Scholar
• Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer 2006; 95: 266–271
   PubMed Web of Science ®Google Scholar
• Mariani A, Webb M J, Keeney G L, Aletti G, Podratz K C. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynaecological Oncology 2002a; 86: 38–44
   PubMed Web of Science ®Google Scholar
• Mariani A, Webb M J, Keeney G L, Haddock M G, Aletti G, Podratz K C. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynaecological Oncology 2002b; 87: 112–117
   PubMed Web of Science ®Google Scholar
• Mariani A, Webb M J, Keeney G L, Haddock M G, Calori G, Podratz K C. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary. American Journal of Obstetrics and Gynecology 2000; 182: 1506–1519
   PubMed Web of Science ®Google Scholar
• Martinez A A, Weiner S, Podratz K, Armin A R, Stromberg J S, Stanhope R, et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecologic Oncology 2003; 90: 537–546
   PubMedGoogle Scholar
• McCormick T C, Cardenes H, Randall M E. Early-stage endometrial cancer: is intravaginal radiation therapy alone sufficient therapy. Brachytherapy 2002; 1: 61–65
   PubMedGoogle Scholar
• McMeekin D S, Lashbrook D, Gold M, Johnson G, Walker J L, Mannel R. Analysis of FIGO Stage IIIc Endometrial Cancer Patients. Gynecologic Oncology 2001; 81: 273–278
   PubMedGoogle Scholar
• Mehta N, Yamada S D, Rotmensch J, Mundt A J. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2003; 57: 1004–1009
   PubMed Web of Science ®Google Scholar
• Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynaecological Oncology Group study. Gynaecological Oncology 1991; 40: 55–65
   PubMed Web of Science ®Google Scholar
• Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynaecological Oncology 1999; 75: 211–214
   PubMed Web of Science ®Google Scholar
• Ng T Y, Nicklin J L, Perrin L C, Cheuk R, Crandon A J. Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma. Gynecologic Oncology 2001; 81: 193–195
   PubMedGoogle Scholar
• Nout R A, Putter H, Jurgenliemk-Schulz I M, Jobsen J J, Lutgens L C, Van Der Steen-Banasik E M, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. ASCO Meeting Abstracts 2008; 26: 5503
   Google Scholar
• Orton J, Blake P, on behalf of AENC. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: Results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. ASCO Meeting Abstracts 2007; 25: 5504
   Google Scholar
• Pitson G, Colgan T, Levin W, Lockwood G, Manchul L, Milosevic M, et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. International Journal of Radiation Oncology, Biology, Physics 2002; 53: 862–867
   PubMedGoogle Scholar
• Potish R A, Twiggs L B, Adcock L L, Savage J E, Levitt S H, Prem K A. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstetrics and Gynecology 1985; 65: 251–256
   PubMed Web of Science ®Google Scholar
• Poulsen H K, Jacobsen M, Bertelsen K, Andersen J E, Ahrons S, Bock J, et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases. International Journal of Gynaecological Cancer. International Journal of Gynaecological Cancer 1996; 6: 38–43
   Google Scholar
• Randall M E, Filiaci V L, Muss H, Spirtos N M, Mannel R S, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynaecological Oncology Group Study. Journal of Clinical Oncology 2006; 24: 36–44
   PubMed Web of Science ®Google Scholar
• Stewart K D, Martinez A A, Weiner S, Podratz K, Stromberg J S, Schray M, et al. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. International Journal of Radiation Oncology, Biology, Physics 2002; 54: 527–535
   PubMedGoogle Scholar
• Straughn J M, Huh W K, Orr J W, Jr., Kelly F J, Roland P Y, Gold M A, et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecologic Oncology 2003; 89: 295–300
   PubMed Web of Science ®Google Scholar
• Straughn J M, Jr., Huh W K, Kelly F J, Leath C A, 3rd, Kleinberg M J, Hyde J, Jr., et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecologic Oncology 2002; 84: 194–200
   PubMed Web of Science ®Google Scholar
• Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecological Oncology Group study. Gynecologic Oncology 2008; 108: 226–233
   PubMed Web of Science ®Google Scholar
• Sutton G, Axelrod J H, Bundy B N, Roy T, Homesley H D, Malfetano J H, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynaecological oncology group study. Gynecologic Oncology 2005; 97: 755–763
   PubMed Web of Science ®Google Scholar
• Turner B C, Knisely J P, Kacinski B M, Haffty B G, Gumbs A A, Roberts K B, et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. International Journal of Radiation Oncology, Biology, Physics 1998; 40: 77–84
   PubMedGoogle Scholar